N. Cichanowitz

800 total citations · 1 hit paper
11 papers, 612 citations indexed

About

N. Cichanowitz is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, N. Cichanowitz has authored 11 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 4 papers in Dermatology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in N. Cichanowitz's work include Psoriasis: Treatment and Pathogenesis (8 papers), Dermatology and Skin Diseases (4 papers) and Autoimmune Bullous Skin Diseases (3 papers). N. Cichanowitz is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Dermatology and Skin Diseases (4 papers) and Autoimmune Bullous Skin Diseases (3 papers). N. Cichanowitz collaborates with scholars based in United States, Canada and Germany. N. Cichanowitz's co-authors include Carmen La Rosa, Kim Papp, Andrew Blauvelt, Kristian Reich, Alexa B. Kimball, Diamant Thaçi, Rodney Sinclair, Stephen K. Tyring, Kenneth Liu and Qing Li and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and British Journal of Dermatology.

In The Last Decade

N. Cichanowitz

11 papers receiving 598 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

2017 413 citations Kristian Reich, Kim Papp et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Cichanowitz United States	6	479	335	146	98	96	11	612
Junichi Sugai Japan	9	496 1.0×	293 0.9×	85 0.6×	68 0.7×	58 0.6×	19	639
Tianshuang Wu United States	9	395 0.8×	483 1.4×	174 1.2×	152 1.6×	70 0.7×	21	735
R. Jiménez‐Puya Spain	12	401 0.8×	232 0.7×	69 0.5×	73 0.7×	73 0.8×	28	567
Catherine Arendt Belgium	8	216 0.5×	136 0.4×	87 0.6×	182 1.9×	54 0.6×	21	446
C. Horreau France	5	459 1.0×	203 0.6×	69 0.5×	175 1.8×	61 0.6×	6	604
Achim Guettner Switzerland	8	436 0.9×	325 1.0×	109 0.7×	83 0.8×	79 0.8×	10	558
Canelle Mazaud France	5	296 0.6×	173 0.5×	59 0.4×	73 0.7×	42 0.4×	6	390
Deepak M.W. Balak Netherlands	11	268 0.6×	238 0.7×	99 0.7×	109 1.1×	45 0.5×	20	513
Marit Saunes Norway	13	252 0.5×	285 0.9×	119 0.8×	62 0.6×	58 0.6×	20	529
Hugo Oliveira Portugal	8	378 0.8×	191 0.6×	64 0.4×	76 0.8×	64 0.7×	27	476

Countries citing papers authored by N. Cichanowitz

Since Specialization

Citations

This map shows the geographic impact of N. Cichanowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Cichanowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Cichanowitz more than expected).

Fields of papers citing papers by N. Cichanowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Cichanowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Cichanowitz. The network helps show where N. Cichanowitz may publish in the future.

Co-authorship network of co-authors of N. Cichanowitz

This figure shows the co-authorship network connecting the top 25 collaborators of N. Cichanowitz. A scholar is included among the top collaborators of N. Cichanowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Cichanowitz. N. Cichanowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Kimball, Alexa B., Kim Papp, Kristian Reich, et al.. (2019). Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British Journal of Dermatology. 182(6). 1359–1368. 23 indexed citations

Papp, Kim, Kristian Reich, Andrew Blauvelt, et al.. (2019). Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. Journal of the European Academy of Dermatology and Venereology. 33(6). 1098–1106. 19 indexed citations

Blauvelt, Andrew, Kristian Reich, Kim Papp, et al.. (2018). Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology. 179(3). 615–622. 60 indexed citations

Papp, Kim, Alexa B. Kimball, Andrew Blauvelt, et al.. (2018). EFFECT OF TILDRAKIZUMAB ON PERSONAL RELATIONSHIPS IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS. 98. 1 indexed citations

Crowley, Jeffrey, Kim Papp, Alan M. Mendelsohn, et al.. (2018). AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders. Annals of the Rheumatic Diseases. 77. 1575–1576. 1 indexed citations

Crowley, Jeffrey, C. Leonardi, Alan Menter, et al.. (2018). SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis. Annals of the Rheumatic Diseases. 77. 1020–1021. 1 indexed citations

Papp, Kim, Kristian Reich, Andrew Blauvelt, et al.. (2018). Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies. SKIN The Journal of Cutaneous Medicine. 2. S4–S4. 4 indexed citations

Gooderham, Melinda, Boni E. Elewski, David M. Pariser, et al.. (2018). THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials. Annals of the Rheumatic Diseases. 77. 364–364. 1 indexed citations

Reich, Kristian, Kim Papp, Andrew Blauvelt, et al.. (2017). Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet. 390(10091). 276–288. 413 indexed citations breakdown →

10.

Boice, Judith A., Thomas Littlejohn, Pedro C. Miranda, et al.. (2007). A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis and Cartilage. 15(12). 1348–1356. 49 indexed citations

11.

Malmström, Kerstin, Paul Kotey, N. Cichanowitz, Stephen Daniels, & Paul J. Desjardins. (2003). Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial. Gynecologic and Obstetric Investigation. 56(2). 65–69. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact